Compare BOW & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | LENZ |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 734.3M | 609.5M |
| IPO Year | 2024 | 2021 |
| Metric | BOW | LENZ |
|---|---|---|
| Price | $24.13 | $9.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $32.29 | ★ $45.60 |
| AVG Volume (30 Days) | 159.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.26 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $551,589,000.00 | $19,088,000.00 |
| Revenue This Year | $21.42 | $51.35 |
| Revenue Next Year | $19.41 | $198.33 |
| P/E Ratio | $15.38 | ★ N/A |
| Revenue Growth | ★ 29.58 | N/A |
| 52 Week Low | $21.21 | $8.25 |
| 52 Week High | $41.98 | $50.19 |
| Indicator | BOW | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 45.28 |
| Support Level | $23.72 | $8.25 |
| Resistance Level | $26.17 | $12.70 |
| Average True Range (ATR) | 0.80 | 0.68 |
| MACD | 0.32 | 0.20 |
| Stochastic Oscillator | 84.62 | 81.86 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.